Skip to main content
. Author manuscript; available in PMC: 2017 Jul 10.
Published in final edited form as: Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):86–108. doi: 10.2174/187153010791213100

Table 1.

Widely-used definitions of the Metabolic Syndrome

World Health Organization (adapted from reference [14])
 One of the following:
  Diabetes mellitus
  Impaired glucose tolerance
  Impaired fasting glucose
 Plus any two of the following
  Waist-to-hip ratio >0.9 (men) or >0.85 (women); BMI>30; or both
  Triacylglycerols ≥ 1.7 mmol/L; HDL cholesterol <0.9 mmol/L (men) or <1.0 mmol/L (women); or both
  Blood pressure ≥ 140/90 mmHg
  Microalbuminuria (urinary albumin excretion rate ≥ 20 μg/min or albumin/creatinine ratio ≥ 30 mg/g)
National Cholesterol Education Program Adult Treatment Panel III (adapted from reference [15])
 Any three of the following:
  Fasting glucose ≥ 6.1 mmol/L
  Waist circumference >102 cm (men) or >88 cm (women)
  Triacylglycerols ≥ 1.7 mmol/L
  HDL cholesterol <1.036 mmol/L (men) or <1.295 mmol/L (women)
  Blood pressure ≥ 130/85 mmHg
International Diabetes Federation (adapted from reference [16])
 Must have:
  Waist circumference as defined by sex- and ethnic-specific values
 Plus any two of the following:
  Triacylglycerols ≥ 1.7 mmol/L or treatment
  HDL <1.03 mmol/L (men) or <1.29 mmol/L (women) or treatment
  Blood pressure ≥ 130/85 mmHg or treatment
  Fasting plasma glucose ≥ 5.6 mmol/L or diagnosed type 2 diabetes
AHA/NHLBI (adapted from reference [17])
 Any three of the following:
  Waist circumference ≥ 102 cm (men) or ≥ 88 cm (women)
  Triglycerides ≥ 1.7 mmol/L or drug treatment for elevated triglycerides
  HDL cholesterol <1.03 mmol/L (men) or <1.3 mmol/L (women) or drug treatment for reduced HDL-C
  Blood pressure ≥ 130 mmHg systolic or ≥ 85 mmHg diastolic or drug treatment
  Fasting glucose ≥ 5.6 mmol/L or treatment for elevated glucose